Outputs, Outcomes and Impact of MRC Research: 2012 Report 10: Impacts on the Private Sector 10: Impacts on the Private Sector

Total Page:16

File Type:pdf, Size:1020Kb

Outputs, Outcomes and Impact of MRC Research: 2012 Report 10: Impacts on the Private Sector 10: Impacts on the Private Sector Outputs, outcomes and impact of MRC research: 2012 report 10: Impacts on the private sector 10: Impacts on the private sector Impacts on the private sector Summary The MRC is interested in the contribution that its research has made to the formation and growth of spin out companies. It is hoped that MRC research will lead to discoveries that can be commercially exploited and result in positive economic impacts such as employment, provision of new goods and services, and direct investment into the UK. The formation of spin out companies is one route to this. It is important that the MRC can both describe its contribution in this area and understand better the processes leading to the successful formation of spin out companies. The MRC is not suggesting that the setting up of spin out companies per se is a measure of success. We are interested in the downstream impact realised, as a result of pursuing this route to commercialisation. The MRC has had a spectacular track record in this area. Cambridge Antibody Technology (CAT), formed in 1989, is still noted as the only academic spin out which has resulted in the discovery of a blockbuster treatment (Humira). CAT was acquired by AstraZeneca in 2006 for £702 million, at which time CAT employed more than 300 staff. An earlier route to commercialising MRC research was the formation of Celltech by the National Enterprise Board in 1980, which floated on the stock exchange in 1993 and was bought by the Belgian Pharmaceutical company UCB in 2004 for £1.53 billion. At that time, Celltech employed around 1,900 people, 450 of which worked in research and development. In 2006 it was estimated that there were almost 1,250 employees in MRC spin out companies (not including Celltech Group, by then part of UCB Pharma)1. However, with a number of mergers and acquisitions underway, it became difficult to continue to track the contribution that MRC-funded discoveries were making to employment within these larger organisations. MRC-funded research played a significant role in the establishment of some of the earliest biotechnology companies. For example, Biogen was formed in 1978 in Geneva by Kenneth Murray (MRC Mammailian Genome Unit, Edinburgh), Walter Gilbert (Harvard), Philip Sharp (MIT), and Charles Weissmann (Zurich). Both Gilbert and Sharp were subsequently awarded separate Nobel prizes for their contributions to genetics. Biogen is based in the US and a merger between Biogen and IDEC in 2003 formed Biogen Idec Inc. In 2010, Biogen Idec Inc. employed 4,800 staff and generated revenue of $5bn. Kenneth Murray’s work, jointly with that of Heinz Schaller (Heidelberg), provided the basis of the Hepatitis B vaccine developed by Biogen, launched in 1989, and is now marketed by GlaxoSmithKline and Merck as Engerix-B™/Recombivax™. These vaccines have achieved $1bn in annual sales and Biogen has offices across the world including in the UK. Professor Sir Kenneth Murray helped establish the Darwin Trust of Edinburgh which has invested in the training of early career researchers and research infrastructure in Scotland. 108 Outputs, outcomes and impact of MRC research: 2012 report 10: Impacts on the private sector MRC Technology manages and tracks commercial activity from MRC units and institutes, including spin out companies. Now via Researchfish, the MRC also collects information on links to companies that arise via its grant funding to universities, providing a comprehensive picture of these outcomes across the MRC portfolio. The 2012 Researchfish data-gathering exercise has added to our dataset on spin out companies, and the MRC now has evidence of MRC-supported research leading to the creation or growth of 104 companies, 56 of which have been formed since 2006. It is estimated that these companies represent at least 500 new highly skilled jobs in the UK (full list later in this chapter). Data on employment in privately held companies is difficult to obtain and track, so this figure is likely to be an underestimate. While we refer to spin out companies, in 2012 we widened the remit of this section to include feedback on significant interactions with existing private organisations (whether for profit or not-for-profit) where the strategy and/or turnover had developed directly as an output from MRC research. This information is not intended to duplicate details reported under the collaboration section which focuses on bilateral and multi-lateral exchanges of expertise/materials etc, but to capture consultancy, and technology/knowledge transfer arrangements where the transfer is primarily to the private sector. A detailed list of all spin out companies can be found at the Annex to this chapter. Status of companies with a link to MRC research in 2012 There is no accepted categorisation for spin out companies, but we have divided the set of companies into those that are selling a product (classified as ‘product on market’) and those without a product in the market (‘developing products’). Although we acknowledge that many ‘product on market’ companies will also have other active programmes to develop new products, successfully bringing a product or service to market indicates the company is generating new income. The status of companies linked to MRC research is as follows: » 48 companies (46 per cent) had products in development (43 in the UK) and 32 (31 per cent) had products on market (28 in UK). » Two companies (two per cent) were in stages prior to initiating a development programme (either pre- incorporation, just incorporated or seeking funding). » Four companies had ceased trading (four per cent), and nine (nine per cent) had merged or been acquired. Figure 1 shows the status of MRC spin out companies in 2012. The distribution of MRC spin out companies by date of formation is shown in figure 2. Outputs, outcomes and impact of MRC research: 2012 report 109 10: Impacts on the private sector Figure 1: Status of spin out companies in 2012 No longer trading Pre-incorporated 4% 2% Acquired/Merged 9% Seeking partners/ funding 8% Product in development 46% Product on market 31% Figure 2: Date of formation of MRC spin out companies 12 10 8 6 4 2 0 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 110 Outputs, outcomes and impact of MRC research: 2012 report 10: Impacts on the private sector There are nine companies that have merged with, or been acquired by, another company, representing ‘exits’. The dates of these are in table 1. Table 1: Date of exit for companies with a link to MRC research MRC linked company Now owned by/part of Date of exit Deal Value2 Cambridge Genetics Ltd Galapagos group 2000 £28m Therexsys Vectura Group plc 2000 £20m Domantis Ltd GlaxoSmithKline 2001 £230m Prolifix Ltd Topo Target A/S 2002 merger Ribotargets Vernalis 2003 £25m Oxxon Therapeutics Ltd Oxford BioMedica 2007 £16m Thiakis Ltd Pfizer 2008 £100m NovaThera Ltd MedCell Biosciences Ltd 2008 merger Aptuscan Ltd Avacta Ltd 2012 £1.5m In the Researchfish data, the details of only four companies (Ardana Biosciences, Metris Therapeutics, Sophos Therapuetics and Virogen) that have ceased trading are included. This is a low rate of failure, as studies have shown that typically 25 per cent of high-technology firms will fail in the first four years, and between 60 and 70 per cent will fail within eight to ten years3. A recent UK survey of university spin out companies4 which gathered details of 820 spin outs from 150 institutions found that 73 per cent of these were more than five years old and still active, and 61 per cent were more than ten years old. This survey also notes that fewer than 10 per cent of companies have achieved a successful exit in the last 10 years, although the returns can be significant (for example, the sale of Thiakis by Imperial College). Employment in companies with a link to MRC research In 2010 we aimed to collect additional data on the employees in companies with a link to MRC research. It is challenging to obtain accurate data on employment within these companies, and there will be a large degree of uncertainty in this information. Researchers were asked to select the current number of employees from a drop down of ranges (1-4, 5-9, 10-19, 20-49 etc). The lowest number in the range, for UK-based companies, is entered into this table, except where researchers provided a comment on the actual current number of employees in the company (these entries are marked *), or where we have cross referenced employment data in other sources (these are referenced). Outputs, outcomes and impact of MRC research: 2012 report 111 10: Impacts on the private sector Company Estimated Staff Abcodia 5 Activiomics Ltd 1 Aquila Biomedical 35 Aurum Biosciences Ltd 56 Bicycle Therapeutics 1 Bioscience Ventures ltd 1 Cambridge Epigenetix 1 Cambridge Neuroimaging 0 Celentyx Ltd N/A CellCentric Ltd 10 Celleron Therapeutics 1 Clarinnis Biosciences Ltd 2* Cytoprom 1 DefiniGEN 1 Deliverics 1 D-Gen 1 Dioptica Scientific Ltd 1 Dundee Cell Products 5* Edinburgh Molecular Imaging Ltd 0 EvoCell 5 FibromEd 0 Fios Genomics Ltd 2* Gamma Technologies Ltd 0 GlycoBioChem 47 Heptares Therapeutics 50 i2eye Diagnostics Ltd N/A Iclectus Ltd 0 Imanova Ltd 588 Innovative Vector Control Consortium 20 Intellihep 1 IR Pharma 1 Kesios Therapeutics Ltd 0 Medannex Ltd 1 MesoLens Ltd 0 nanoTherics Ltd 5 NeurocentRx 1 North East Proteome Analysis Facility (NEPAF) 1 Nottingham Prognostics Ltd 1 Novocellus N/A Nuada Medical Group 20 Ovatus Ltd 1 Oxford Contrast Molecular Diagnostics 0 Oxford Gene Technology (OGT) 609 Oxford Nanopore Technologies (ONT) 13010 P1 Vital 10 112 Outputs, outcomes and impact of MRC research: 2012 report 10: Impacts on the private sector Pentraxin Therapeutics 0 Perspectum Diagnostics 1 Phagenesis Limited 1 Pharmatics Ltd 1 Platelet Solutions Limited 1 Pro-Cure Therapeutics Limited 10* Promethean Particles 1 Protein Logic N/A Renovo 011 ReOx 1 Riotech Pharmaceuticals Ltd 1 Science Capital 0 Senectus Therapeutics 1 Senexis Ltd 1 Serascience Ltd N/A Sesmos Ltd 5 Sophos Therapuetics 0 SubZepto Associates Consulting 0 Summit plc.
Recommended publications
  • Biochemistry and the Genomic Revolution 1.1
    Dedication About the authors Preface Tools and Techniques Clinical Applications Molecular Evolution Supplements Supporting Biochemistry, Fifth Edition Acknowledgments I. The Molecular Design of Life 1. Prelude: Biochemistry and the Genomic Revolution 1.1. DNA Illustrates the Relation between Form and Function 1.2. Biochemical Unity Underlies Biological Diversity 1.3. Chemical Bonds in Biochemistry 1.4. Biochemistry and Human Biology Appendix: Depicting Molecular Structures 2. Biochemical Evolution 2.1. Key Organic Molecules Are Used by Living Systems 2.2. Evolution Requires Reproduction, Variation, and Selective Pressure 2.3. Energy Transformations Are Necessary to Sustain Living Systems 2.4. Cells Can Respond to Changes in Their Environments Summary Problems Selected Readings 3. Protein Structure and Function 3.1. Proteins Are Built from a Repertoire of 20 Amino Acids 3.2. Primary Structure: Amino Acids Are Linked by Peptide Bonds to Form Polypeptide Chains 3.3. Secondary Structure: Polypeptide Chains Can Fold Into Regular Structures Such as the Alpha Helix, the Beta Sheet, and Turns and Loops 3.4. Tertiary Structure: Water-Soluble Proteins Fold Into Compact Structures with Nonpolar Cores 3.5. Quaternary Structure: Polypeptide Chains Can Assemble Into Multisubunit Structures 3.6. The Amino Acid Sequence of a Protein Determines Its Three-Dimensional Structure Summary Appendix: Acid-Base Concepts Problems Selected Readings 4. Exploring Proteins 4.1. The Purification of Proteins Is an Essential First Step in Understanding Their Function 4.2. Amino Acid Sequences Can Be Determined by Automated Edman Degradation 4.3. Immunology Provides Important Techniques with Which to Investigate Proteins 4.4. Peptides Can Be Synthesized by Automated Solid-Phase Methods 4.5.
    [Show full text]
  • Professor Michael Neuberger: Biochemist Behind Life-Saving
    Professor Michael Neuberger: Biochemist behind life-saving ... http://www.independent.co.uk/news/obituaries/professor-mich... THE INDEPENDENT FRIDAY 08 NOVEMBER 2013 NEWS VOICES SPORT TECH LIFE PROPERTY ARTS + ENTS TRAVEL MONEY INDYBEST BLOGS UK World Business People Science Environment Media Technology Education Obituaries Diary 1 of 15 08/11/2013 10:36 Professor Michael Neuberger: Biochemist behind life-saving ... http://www.independent.co.uk/news/obituaries/professor-mich... News > Obituaries Professor Michael Neuberger: Biochemist behind life-saving work on the immune system He was seen as an outstanding mentor, with his sharp intellect and ability to get to the core issue Friday 01 November 2013 Shares: 28 PRINT A A A FOOD+DRINK Professor Michael Neuberger was pivotal to the ADS BY GOOGLE great advances in biomedical research, with his You Could Be Owed unravelling of the mysteries of human £2400 If You've Ever Had A Loan antibodies. A Fellow of Trinity College, You Could Be Owed A Cambridge where he was a director of studies in Refund Natural Sciences, he was also deputy director of LloydsTSB.BankRefunds.ne t Cambridge’s Medical Research Council FreeWatt Solar PV Laboratory of Molecular Biology (LMB). Biomass Lincs Renewable Energy With the demand for a new class of drugs to Matcha the day: Company of 2012. Heard about the fight diseases, such as cancer, as well as immune Commercial & Domestic soft drink set to be Systems disorders such as rheumatoid arthritis, the the next big thing? www.freewatt.co.uk bio-tech industries have shown rapid growth. Buddhist monks Top10 Broadband in the Over 25 years, Neuberger made significant certainly have – they've UK been enjoying this Broadband From £2.50.
    [Show full text]
  • Clinical Molecular Genetics in the Uk C.1975–C.2000
    CLINICAL MOLECULAR GENETICS IN THE UK c.1975–c.2000 The transcript of a Witness Seminar held by the History of Modern Biomedicine Research Group, Queen Mary, University of London, on 5 February 2013 Edited by E M Jones and E M Tansey Volume 48 2014 ©The Trustee of the Wellcome Trust, London, 2014 First published by Queen Mary, University of London, 2014 The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 0 90223 888 6 All volumes are freely available online at www.history.qmul.ac.uk/research/modbiomed/ wellcome_witnesses/ Please cite as: Jones E M, Tansey E M. (eds) (2014) Clinical Molecular Genetics in the UK c.1975–c.2000. Wellcome Witnesses to Contemporary Medicine, vol. 48. London: Queen Mary, University of London. CONTENTS What is a Witness Seminar? v Acknowledgements E M Tansey and E M Jones vii Illustrations and credits ix Abbreviations xi Ancillary guides xiii Introduction Professor Bob Williamson xv Transcript Edited by E M Jones and E M Tansey 1 Appendix 1 Photograph, with key, of delegates attending The Molecular Biology of Thalassaemia conference in Kolimbari, Crete, 1978 88 Appendix 2 Extracts from the University of Leiden postgraduate course Restriction Fragment Length Polymorphisms and Human Genetics, 1982 91 Appendix 3 Archival material of the Clinical Molecular Genetics Society 95 Biographical notes 101 References 113 Index 131 Witness Seminars: Meetings and Publications 143 WHAT IS A WITNESS SEMINAR? The Witness Seminar is a specialized form of oral history, where several individuals associated with a particular set of circumstances or events are invited to meet together to discuss, debate, and agree or disagree about their memories.
    [Show full text]
  • Journal of Biomedical Discovery and Collaboration
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Journal of Biomedical Discovery and provided by PubMed Central Collaboration BioMed Central Case Study Open Access The emergence and diffusion of DNA microarray technology Tim Lenoir*† and Eric Giannella† Address: Jenkins Collaboratory for New Technologies in Society, Duke University, John Hope Franklin Center, 2204 Erwin Road, Durham, North Carolina 27708-0402, USA Email: Tim Lenoir* - [email protected]; Eric Giannella - [email protected] * Corresponding author †Equal contributors Published: 22 August 2006 Received: 09 August 2006 Accepted: 22 August 2006 Journal of Biomedical Discovery and Collaboration 2006, 1:11 doi:10.1186/1747-5333-1-11 This article is available from: http://www.j-biomed-discovery.com/content/1/1/11 © 2006 Lenoir and Giannella; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract The network model of innovation widely adopted among researchers in the economics of science and technology posits relatively porous boundaries between firms and academic research programs and a bi-directional flow of inventions, personnel, and tacit knowledge between sites of university and industry innovation. Moreover, the model suggests that these bi-directional flows should be considered as mutual stimulation of research and invention in both industry and academe, operating as a positive feedback loop. One side of this bi-directional flow – namely; the flow of inventions into industry through the licensing of university-based technologies – has been well studied; but the reverse phenomenon of the stimulation of university research through the absorption of new directions emanating from industry has yet to be investigated in much detail.
    [Show full text]
  • Blotting Techniques
    BLOTTING TECHNIQUES Dr.Ramesh C.K. Associate Professor and Chairman Department of Biotechnology Sahyadri Science College Shimoga - 577 203 Karnataka, India BLOTTING TECHNIQUES Southern Blot Northern blot Western blot It is used to detect It is used to detect It is used to detect the DNA. the RNA. proteins. SOUTHERN BLOTTING A technique for identifying specific sequences of DNA in which DNA fragments are separated by electrophoresis, transferred to a membrane, and identified with a suitable probe. Detects restriction fragments following a restriction enzyme digest of genomic DNA (RFLPs) Named after British biochemist Edwin Southern (alive and publishing!) Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol Biol. 1975 Nov 5;98(3):503-17. History/Background • ‘Southern’ hybridization named after Sir Edwin Southern • Developed in 1975 • One of the most highly cited scientific publications “Used to detect the DNA” • This method Involves: Separation Transfer Hybridization. • This DNA can be: • Single gene • Part of a larger piece of DNA……..viral genome “The key to this method is Hybridization” Hybridization “Process of forming a dsDNA molecule between a ssDNA probe and a ss-target DNA” PRINCIPLE The mixture of molecules is separated. Immobilized on a matrix. Probe addition to the matrix to bind to the molecules. Unbound probes are removed. “The place where the probe is connected corresponds to the location of the immobilized target molecule.” Steps The DNA is digested Fragments Gel electrophoresis Transfer to membrane Probing Autoradiogram I. DNA Purification – Isolate the DNA in question from the rest of the cellular material in the nucleus.
    [Show full text]
  • HUMAN GENE MAPPING WORKSHOPS C.1973–C.1991
    HUMAN GENE MAPPING WORKSHOPS c.1973–c.1991 The transcript of a Witness Seminar held by the History of Modern Biomedicine Research Group, Queen Mary University of London, on 25 March 2014 Edited by E M Jones and E M Tansey Volume 54 2015 ©The Trustee of the Wellcome Trust, London, 2015 First published by Queen Mary University of London, 2015 The History of Modern Biomedicine Research Group is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 1 91019 5031 All volumes are freely available online at www.histmodbiomed.org Please cite as: Jones E M, Tansey E M. (eds) (2015) Human Gene Mapping Workshops c.1973–c.1991. Wellcome Witnesses to Contemporary Medicine, vol. 54. London: Queen Mary University of London. CONTENTS What is a Witness Seminar? v Acknowledgements E M Tansey and E M Jones vii Illustrations and credits ix Abbreviations and ancillary guides xi Introduction Professor Peter Goodfellow xiii Transcript Edited by E M Jones and E M Tansey 1 Appendix 1 Photographs of participants at HGM1, Yale; ‘New Haven Conference 1973: First International Workshop on Human Gene Mapping’ 90 Appendix 2 Photograph of (EMBO) workshop on ‘Cell Hybridization and Somatic Cell Genetics’, 1973 96 Biographical notes 99 References 109 Index 129 Witness Seminars: Meetings and publications 141 WHAT IS A WITNESS SEMINAR? The Witness Seminar is a specialized form of oral history, where several individuals associated with a particular set of circumstances or events are invited to meet together to discuss, debate, and agree or disagree about their memories. The meeting is recorded, transcribed, and edited for publication.
    [Show full text]
  • Blotting Techniques M.W
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector RESEARCH TECHNIQUES MADE SIMPLE North, South, or East? Blotting Techniques M.W. Nicholas1 and Kelly Nelson2 Journal of Investigative Dermatology (2013) 133, e10; doi:10.1038/jid.2013.216 One of the cornerstones of modern molecular biology, blotting is a powerful and sensitive technique for identifying WHAT BLOTTING DOES the presence of specific biomolecules within a sample. • Blotting allows specific and sensitive detection of a Subtypes of blotting are differentiated by the target protein (western) or specific DNA or RNA sequence molecule that is being sought. The first of these tech­ (Southern, northern) within a large sample isolate. niques developed was the Southern blot, named for Dr. • Targets are first separated by size/charge via gel Edwin Southern, who developed it to detect specific DNA electrophoresis and then identified using a very sequences (Southern, 1975). Subsequently, the method was sensitive probe. modified to detect other targets. The nomenclature of these • Variations of these techniques can detect post­ techniques was built around Dr. Southern’s name, resulting translational modifications and DNA­bound proteins. in the terms northern blot (for detection of RNA), western blot (for detection of protein), eastern blot (for detection • Western blotting may also be used to detect a of posttranslationally modified proteins), and south­ circulating antibody in a patient sample or confirm western blot (for detection of DNA binding proteins). Most an antibody’s specificity. researchers consider the eastern blot and the southwestern blot variations of western blots rather than distinct entities.
    [Show full text]
  • Oxalate Oxidase Quantification and Relative Mrna Expression in Transgenic American Chestnut (Castanea Dentata)
    SUNY College of Environmental Science and Forestry Digital Commons @ ESF Dissertations and Theses Spring 4-27-2020 Oxalate Oxidase Quantification and Relative Mrna Expression in Transgenic American Chestnut (Castanea Dentata) Dakota Matthews SUNY College of Environmental Science and Forestry, [email protected] Follow this and additional works at: https://digitalcommons.esf.edu/etds Part of the Forest Biology Commons Recommended Citation Matthews, Dakota, "Oxalate Oxidase Quantification and Relative Mrna Expression in Transgenic American Chestnut (Castanea Dentata)" (2020). Dissertations and Theses. 175. https://digitalcommons.esf.edu/etds/175 This Open Access Thesis is brought to you for free and open access by Digital Commons @ ESF. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of Digital Commons @ ESF. For more information, please contact [email protected], [email protected]. OXALATE OXIDASE QUANTIFICATION AND RELATIVE MRNA EXPRESSION IN TRANSGENIC AMERICAN CHESTNUT (CASTANEA DENTATA) by Dakota Matthews A thesis submitted in partial fulfillment of the requirements for the Masters of Science Degree State University of New York College of Environmental Science and Forestry Syracuse New York May 2020 Approved by: Dr. William A. Powell, Major Professor Dr. Stephen Shaw, Examining Committee Dr. Melissa K. Fierke, Department Chair S. Scott Shannon, Dean, The Graduate School i Acknowledgements I am extremely grateful to have been able to work on the American chestnut research and restoration project here at SUNY-ESF. This project would not have been possible without the support from many individuals. I would first like to thank my major professor Dr. William A. Powell, who has taught me so much and been extremely patient with me.
    [Show full text]
  • Molecular Techniques in Radiobiology Introduction The
    Introduction • The birth of molecular biology could be ascribed to the discovery of the structure of DNA by Watson Molecular Techniques in and Francis Crick in 1953 Radiobiology • In the late 1940s and early 1950s, Linus Pauling realized that as amino acids were folded into proteins, they formed three-dimensional structures, and that function was related to the structure th Chapter 16 (6 edition) • The whole concept emerged that the sequence of bases, which coded for a protein, ultimately Eric J. Hall., Amato Giaccia, determined function leading the way to breaking the genetic code Radiobiology for the Radiologist The structure of DNA The structure of DNA • DNA - deoxyribonucleic acid is a polymer with the • DNA molecule has many monomer units of nucleotides deoxyribo-nucleotides (bases) linked in a chain- • Each nucleotide consists of a 5-carbon sugar like arrangement (deoxyribose), a nitrogen containing base attached to the sugar, and a phosphate group • Bases are held by hydrogen bonds and are • There are four different types of nucleotides found in paired complimentary: DNA, differing only in – adenine with thymine the nitrogenous base: – cytosine with guanine A is for adenine • Each half constitutes a G is for guanine template for C is for cytosine reconstruction of the T is for thymine other half RNA and DNA Transcription and translation • RNA – ribonucleic acid, has ribose sugar molecule The flow of genetic information from DNA to protein (gene instead of deoxyribose expression) requires a series of steps: • In the cell RNA is
    [Show full text]
  • Science and the Sustainable Intensification of Global Agriculture
    Reaping the benefits Science and the sustainable intensification of global agriculture October 2009 Cover image: From an illustration of a push-pull system for pest control, courtesy of The Gatsby Charitable Foundation. The Quiet Revolution: Push-Pull Technology and the African Farmer. Gatsby Charitable Foundation 2005. Reaping the benefi ts: science and the sustainable intensifi cation of global agriculture RS Policy document 11/09 Issued: October 2009 RS1608 ISBN: 978-0-85403-784-1 © The Royal Society, 2009 Requests to reproduce all or part of this document should be submitted to: The Royal Society Science Policy 6–9 Carlton House Terrace London SW1Y 5AG Tel +44 (0)20 7451 2500 Email [email protected] Web royalsociety.org Design by Franziska Hinz, Royal Society, London Copyedited and Typeset by Techset Composition Limited Reaping the benefi ts: science and the sustainable intensifi cation of global agriculture Contents Foreword v Membership of working group vii Summary ix 1 Introduction 1 1.1 An urgent challenge 1 1.2 Trends in food crop production 2 1.3 Science in context 5 1.4 The need for sustainable intensifi cation 6 1.5 Agricultural sustainability 7 1.6 Agriculture and sustainable economic development 7 1.7 Other major studies 8 1.8 Further UK work 9 1.9 About this report 9 1.10 Conduct of the study 10 2 Constraints on future food crop production 11 2.1 Climate change 11 2.2 Water 11 2.3 Temperature 12 2.4 Ozone 13 2.5 Soil factors 13 2.6 Crop nutrition 15 2.7 Pests, diseases and weed competition 16 2.8 Energy and greenhouse
    [Show full text]
  • Royal Medals 2012 Congratulations to Professor Peter Higgs FRS
    July 2012 Royal Medals 2012 Her Majesty The Queen has approved the Council’s recommendation that the RSE’s Royal Medals for 2012 should be awarded to: Professor David Milne OBE FREng FRSE (left) for his outstanding contribution to business and commerce in Scotland, and to Professor Sir Edwin Southern FRS HonFRSE (centre) for his outstanding contribution to molecular biology. We are delighted that HRH The Duke of Edinburgh will present the Medals at the RSE during the early afternoon of 26 September 2012. The Duke will also present the 2012 IEEE/RSE/ Wolfson James Clerk Maxwell Award to Professor Gerhard Sessler (right), Darmstadt University of Technology. Fellows are most welcome to attend. There will be a tea with HRH thereafter. To apply for admission tickets, please email: [email protected] or contact the Events Team on 0131 240 2780. There is no charge, but only those with formal admission cards will be able to attend. If you wish to be accompanied by your spouse/partner or a personal guest, please indicate this when you apply for tickets, which are being issued on a first-come, first-served basis. Congratulations to Professor Peter Higgs FRS FRSE The RSE wishes to congratulate Professor Peter Higgs FRS FRSE and the team at CERN on the recent announcement that they have discovered a new particle consistent with the Higgs boson. Ballot for Council and Office Bearers Ballot forms were issued to all Fellows at the beginning of July for the election of RSE Council and Office Bearers. Fellows are reminded to return their ballot forms, in the envelope provided with the form, no later than Wednesday 15 August 2012.
    [Show full text]
  • Communicating Biochemistry: Meetings and Events
    © The Authors. Volume compilation © 2011 Portland Press Limited Chapter 3 Communicating Biochemistry: Meetings and Events Ian Dransfield and Brian Beechey Scientific conferences organized by the Biochemical Society represent a key facet of activity throughout the Society’s history and remain central to the present mission of promoting the advancement of molecular biosciences. Importantly, scientific conferences are an important means of communicating research findings, establishing collaborations and, critically, a means of cementing the community of biochemical scientists together. However, in the past 25 years, we have seen major changes to the way in which science is communicated and also in the way that scientists interact and establish collabo- rations. For example, the ability to show videos, “fly through” molecular structures or show time-lapse or real-time movies of molecular events within cells has had a very positive impact on conveying difficult concepts in presentations. However, increased pressures on researchers to obtain/maintain funding can mean that there is a general reluctance to present novel, unpublished data. In addition, the development of email and electronic access to scientific journals has dramatically altered the potential for communi- cation and accessibility of information, perhaps reducing the necessity of attending meetings to make new contacts and to hear exciting new science. The Biochemical Society has responded to these challenges by progressive development of the meetings format to better match the
    [Show full text]